Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III rAd-IFN plus celecoxib and gemcitabine versus celecoxib and gemcitabine in previously treated malignant pleural mesothelioma
2017-003169-82Phase 3Unknown
- Sponsor
- Trizell GmbH
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nadofaragene firadenovec, gemcitabine and celecoxib in pleural mesothelioma (2 arms), sponsored by Trizell GmbH. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
nadofaragene firadenovecgemcitabinecelecoxib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2017-003169-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003169-82.